Istari Oncology Inc.

Istari Oncology, Inc., is a clinical-stage biotechnology company developing innovative immunotherapies for the treatment of patients with solid tumors. Istari has built a passionate and experienced leadership team focused on clinical trial strategy and driving execution while seeking opportunities for partnership and collaboration with the world’s leading cancer centers and oncology biotech firms. Our principal asset is lerapolturev, an investigational immunotherapy based on the Sabin oral poliovirus vaccine, genetically engineered to eliminate neurotoxicity and leverage multiple unique mechanisms of action to activate a systemic antitumor response to fight cancer.